WuXi news

17 September 2025
WuXi Biologics Gains GMP Certification for Three Facilities from Turkey's TITCK
Three WuXi facilities passed TITCK's inspection, reinforcing their global quality standards and expanding into the Turkish market.
14 May 2025
WuXi Biologics Sells Leverkusen Plant to Terumo
The Leverkusen plant sale aligns with WuXi's strategy to focus on large-scale DP manufacturing in Singapore, enhancing global client solutions and optimizing asset returns. Completion expected in 2025.
6 January 2025
MSD Ireland to Acquire WuXi Vaccines' Dundalk Facility
The acquisition involves a €500M investment, adding 1,000 jobs across Ireland by 2025, enhancing vaccine production capabilities and strengthening Ireland's pharma sector.
6 December 2024
WuXi Biologics Hits Key Milestones at Ireland Site with 16,000L PPQ Success and HPRA GMP Approvals
The Dundalk site completed two successful PPQ runs and received GMP approval, enhancing its role in global biomanufacturing with innovative, sustainable processes and strong regulatory compliance.
16 January 2020
WuXi Biologics Acquires Bayer's Drug Plant in Germany
The plant will serve as a back-up site for Kovaltry™ production. The deal includes equipment purchase and a long-term lease. Financial details undisclosed.
22 November 2019
WuXi Vaccines to Invest $240M in New Ireland Facility
The new facility in Dundalk will create 200 jobs, produce vaccines for a global pharma, and enhance Ireland's life sciences ecosystem, pending planning approval.

What's WuXi up to in Europe?

Find out with chemXplore Analytics

5 December 2018
WuXi Biologics Begins Building Major Biomanufacturing Facility in Ireland
Construction starts on a new facility in Dundalk, Ireland, featuring advanced bioprocessing technology and supported by the Irish Government, enhancing global biomanufacturing capabilities.